Motif Bio PLC | Ownership
Companies that own Motif Bio PLC
Invesco Asset Management Ltd.
43,649,260
14.71%
-10,908,000
0.02%
03/01/2018
HSBC Global Asset Management (UK) Ltd.
24,055,741
8.11%
707,500
0.01%
06/29/2018
M&G Investment Management Ltd.
15,177,151
5.12%
15,177,151
0.01%
08/13/2018
Sand Grove Capital Management LLP
11,290,322
3.81%
-1,967,126
0.36%
05/23/2018
Merrill Lynch, Pierce, Fenner & Smith, Inc. (Invt Mgmt)
8,866,382
2.99%
-13,175,383
0%
06/06/2018
Astor Investment Advisors SIM SpA
2,375,381
0.8%
1,408,865
5.62%
06/29/2018
Baader Bank AG (Investment Management)
1,260,885
0.43%
-37,406
0.24%
06/29/2018
Gies und Heimburger GmbH
956,000
0.32%
296,500
0.78%
02/28/2018
DWS Investment GmbH
600,000
0.2%
0
0%
06/29/2018
Teton Advisors, Inc. (Investment Management)
160,000
0.05%
160,000
0.01%
06/30/2018
| Address |
5 Independence Way
Princeton New Jersey 08540
United States
|
|
Employees
|
- |
| Website |
https://www.motifbio.com/ |
| Updated |
07/08/2019 |
| Motif Bio Plc is a clinical stage biopharmaceutical company which develops novel antibiotics designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria. It pipeline of antibiotics includes iclaprim, and MTF-001, a preclinical program to design a dihydrofolate reductase inhibitor (DHFRi). The company was founded on November 20, 2014 and is headquartered in New York, NY. |
